Definium Therapeutics (DFTX) CFO Roberts Sells $136K of Stock
CFO Brandi Roberts sold 3,013 shares of Definium Therapeutics on June 25, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Brandi Roberts, Chief Financial Officer at Definium Therapeutics, Inc. ($DFTX), sold 3,013 shares at an average price of $45.03, worth about $135,675.39, on June 25, 2026. The trade was reported to the SEC in a Form 4 filing and was made under a pre-arranged Rule 10b5-1 trading plan.
Since the trade, $DFTX is down 1.3% after 1 week, down 4.8% after 1 month and down 28.3% to date (from the $44.79 close on Jun 25, 2026).
DFTX
Definium Therapeutics, Inc.
Key Points
- Brandi Roberts, CFO of Definium Therapeutics, sold 3,013 shares at an average price of $45.03, totaling $135,675 on June 25, 2026.
- Definium Therapeutics, with a market cap of $5.97 billion, has a 52-week range between $6.40 and $47.01 and a beta of 2.378.
- Analysts maintain a 'strong buy' consensus with a target mean price of $56.00, supported by recent insider sales.
Get $DFTX trade alerts by text
We text you when insiders, Congress or big funds trade $DFTX. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Definium Therapeutics, Inc. alert may contain errors. Disclosures
On June 25, 2026, Brandi Roberts, the Chief Financial Officer of Definium Therapeutics, Inc. (NasdaqGS: DFTX), sold 3,013 shares of the company. The shares were sold at an average price of $45.03, resulting in a total transaction value of $135,675. This sale was conducted under a pre-arranged trading plan.
Insider Buying and Selling at Definium Therapeutics, Inc.
Alongside Brandi Roberts, several other executives at Definium Therapeutics also sold shares on June 25, 2026. CEO Robert Barrow sold 29,208 shares, Chief Medical Officer Daniel Karlin sold 10,035 shares, Chief Legal Officer Mark Sullivan sold 13,008 shares, and Chief Commercial Officer Matthew Wiley sold 2,867 shares. All these transactions were executed at an average price of $45.03 per share and were part of planned sales.
Definium Therapeutics, Inc. Stock Up 15.8%
Shares of NasdaqGS: DFTX traded near $44.95 on Saturday. Definium Therapeutics has a market capitalization of approximately $5.97 billion. The stock has experienced significant volatility with a 52-week low of $6.40 and a high of $47.01. The company has a 50-day moving average of $24.52 and a 200-day moving average of $17.07. Despite its growth potential, the company is not yet profitable, reflected by its negative forward P/E ratio of -28.83.
Analysts Set New Price Targets
Recently, several analysts have maintained their 'buy' ratings for Definium Therapeutics. On June 24, 2026, Jones Trading reaffirmed its buy rating with a price target of $74.0. Baird and Needham also maintained their buy ratings on June 23, with targets of $57.0 and $50.0, respectively. The consensus among 15 analysts is a strong buy, with an average target price of $56.00.
About Definium Therapeutics
Definium Therapeutics, Inc. is a biopharmaceutical company focused on developing treatments for brain health disorders. Based in New York, the company is advancing its lead product candidates, DT120 and DT402, through clinical trials to address conditions like generalized anxiety disorder and autism spectrum disorder. Led by CEO Robert Barrow, the company employs 105 people and operates in the biotechnology industry.
Bottom Line
Brandi Roberts' recent sale of shares in Definium Therapeutics is part of a broader trend of insider transactions at the company. Investors often watch these moves closely, although they do not necessarily indicate the company's future performance. As Definium Therapeutics continues to develop its innovative treatments, the market will be watching for its next earnings report on July 30, 2026.
Related Filing Alerts
Source: Brandi Roberts's Form 4 filing on $DFTX (Jun 25, 2026). Find the original filing: DFTX Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts